Evelo Biosciences (NASDAQ:EVLO) posted its quarterly earnings data on Thursday. The company reported ($0.63) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.08, MarketWatch Earnings reports.
NASDAQ EVLO traded down $0.17 during trading hours on Friday, reaching $3.81. The company’s stock had a trading volume of 287,552 shares, compared to its average volume of 134,286. The firm’s 50-day moving average price is $4.30 and its 200-day moving average price is $4.56. The company has a quick ratio of 4.89, a current ratio of 4.89 and a debt-to-equity ratio of 0.50. Evelo Biosciences has a 1 year low of $3.01 and a 1 year high of $9.27.
A number of research firms have recently weighed in on EVLO. Morgan Stanley cut Evelo Biosciences from an “overweight” rating to an “equal weight” rating and set a $8.00 price objective on the stock. in a research report on Thursday, May 21st. Zacks Investment Research cut Evelo Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, July 21st. BMO Capital Markets lowered their price target on Evelo Biosciences from $21.00 to $17.00 and set an “outperform” rating on the stock in a report on Thursday, July 2nd. Finally, Jefferies Financial Group cut Evelo Biosciences from a “buy” rating to a “hold” rating and lowered their price target for the stock from $18.00 to $6.00 in a report on Tuesday, May 12th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $8.81.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.
Further Reading: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.